NCT05870202 (TBQ) is a clinical trial of screening tool in Type 2 Diabetes, sponsored by University of Minnesota.

Who is sponsoring NCT05870202?

NCT05870202 is sponsored by University of Minnesota.

What drugs are being tested in NCT05870202?

Interventions in NCT05870202: screening tool.

What condition does NCT05870202 study?

NCT05870202 studies Type 2 Diabetes.

Is NCT05870202 still recruiting?

NCT05870202 is currently completed. Last updated 24 April 2025.

Last reviewed 2025-04-24 · How we verify

NCT05870202: TBQ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment Burden Screening Questionnaire Pilot Study

Completed Last updated 24 April 2025

What this trial tests

trial testing screening tool in Type 2 Diabetes in 64 participants. Completed in 1 April 2025.

Timeline

7 March 2023

Primary endpoint
15 May 2024

1 April 2025

Quick facts

Lead sponsor	University of Minnesota
Status	Completed
Study type	OBSERVATIONAL
Enrollment	64
Start date	7 March 2023
Primary completion	15 May 2024
Estimated completion	1 April 2025
Sites	2 locations across United States

Drugs / interventions tested

screening tool

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

University of Minnesota

Who can join

Adults 18 to 95, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study is to develop and evaluate a clinic-based pilot intervention to optimize patient-centered diabetes care for low income patients at risk for low quality diabetes care and poor outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other University of Minnesota trials

Trials by the same sponsor.

NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05870202 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
Last refreshed: 24 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05870202.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing